Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, semaglutide demonstrates measurable efficacy for weight loss in clinical studies. The STEP trials showed average weight loss of 15-22% of baseline body weight over 68 weeks at therapeutic doses, compared to 2-3% with placebo. However, individual outcomes vary significantly based on multiple physiological and genetic factors.

Understanding whether semaglutide will work optimally for you requires more than population averages. Genetic variations in GLP-1 receptor sensitivity, metabolic pathways, and appetite regulation can influence how your body responds to treatment. PlexusDx precision wellness approach helps patients explore these personal factors alongside clinical evidence.

Clinical Evidence on Semaglutide Weight Loss Outcomes

The STEP clinical trial program established semaglutide's efficacy through four randomized controlled studies involving over 4,600 participants. At the maximum therapeutic dose of 2.4 mg weekly, average weight loss reached 15.3 kg (22% of baseline weight) over 68 weeks. Weight loss was progressive, with most loss occurring between weeks 8 and 52.

Importantly, not all participants achieved the average result. Approximately 85% of semaglutide users lost at least 5% of body weight, while 70% achieved 10% or greater loss. Roughly 35% achieved the 25% weight loss threshold. These variations highlight that efficacy is real but individual outcomes differ based on metabolic and genetic context.

Genetic and Metabolic Factors Influencing Semaglutide Response

Individual semaglutide efficacy relates partly to genetic variation in GLP-1 receptor function and related metabolic pathways. The GLP1R rs6923761 variant, for example, may influence baseline appetite signaling efficiency. FTO rs9939609 affects metabolic rate and appetite perception. These genetic differences don't determine treatment success but may help provide context for variable responses observed clinically.

Genetic Factor Clinical Relevance to Semaglutide Response
GLP1R rs6923761 variant May influence GLP-1 receptor sensitivity and baseline appetite regulation patterns
FTO rs9939609 variant Associated with metabolic rate and appetite perception, potentially affecting weight loss trajectory
MC4R rs17782313 variant Relates to melanocortin pathway signaling, which intersects with GLP-1 appetite mechanisms
GIPR rs1800437 variant Affects glucose-dependent insulinotropic peptide function, relevant to metabolic response

Metabolic Biomarkers and Treatment Response Patterns

Beyond genetics, baseline metabolic biomarkers correlate with semaglutide response variability. Insulin resistance levels, fasting glucose, and C-reactive inflammation at baseline predict weight loss magnitude in some studies. Patients with higher baseline insulin resistance sometimes show greater initial weight loss, while those with normal insulin sensitivity may achieve steady, moderate losses.

Gastrointestinal tolerance also shapes real-world outcomes. Nausea, constipation, or early satiety affects treatment adherence and dose escalation success. Patients who tolerate dose escalation to 2.4 mg generally see better weight outcomes than those who plateau at lower doses, suggesting individual pharmacodynamic tolerance influences efficacy.

Medical Considerations and Who Semaglutide May Benefit

Semaglutide is FDA-approved for weight loss in adults with BMI 30 or greater, or BMI 27+ with weight-related conditions like hypertension or type 2 diabetes. Medical eligibility requires absence of personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Provider evaluation is essential before starting treatment.

Semaglutide's mechanism—slowing gastric emptying and enhancing satiety signals—works best in patients with preserved appetite drive at baseline. Those with functional dyspepsia, gastroparesis history, or certain pancreatitis patterns may face safety concerns. A provider should assess medication interactions, especially with diabetes drugs or incretin inhibitors, before initiating therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in key peptide pathway genes including GLP1R, GIPR, FTO, and MC4R variants. These genetic insights may help provide context for understanding why semaglutide response varies between individuals. The test should be interpreted with a qualified healthcare provider to avoid misinterpretation as a guaranteed predictor of medication success.

Genetic predispositions revealed in the test relate to baseline appetite regulation, metabolic rate, and insulinotropic signaling efficiency—all pathways semaglutide engages. A patient with certain FTO variants may have different baseline metabolic characteristics than someone with alternative alleles. This information can support a more informed conversation with your provider about realistic expectations and alternative approaches if needed.

Understanding your genetic predispositions through PlexusDx testing is one data point among many—clinical biomarkers, BMI, comorbidities, and prior treatment responses matter equally. Using this information alongside provider expertise helps construct a more complete picture of which weight loss approach may align best with your individual physiology, rather than relying solely on population-level efficacy data.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight will I lose on semaglutide?

Clinical trials show average weight loss of 15-22% of body weight over 68 weeks at therapeutic doses. Individual results vary significantly based on genetics, metabolic health, tolerance, and lifestyle factors. Your provider can help estimate realistic expectations for your situation.

What makes some people lose more weight than others on semaglutide?

Genetic variation in GLP-1 receptor function, baseline insulin sensitivity, metabolic rate, gastrointestinal tolerance, and adherence to dose escalation all influence outcomes. PlexusDx genetic testing may help clarify some of these individual factors.

Does PlexusDx offer semaglutide, and what does it cost?

Yes. PlexusDx offers compounded semaglutide injection from licensed 503A pharmacies at $149/mo, and oral semaglutide from $249/mo. Genetic testing costs $99 as an add-on or $298 standalone.

What are the common side effects of semaglutide for weight loss?

Nausea, vomiting, diarrhea, and constipation are most common, especially during dose escalation. Most improve over weeks. Serious risks include pancreatitis, gallbladder issues, and acute kidney injury in rare cases. Medical supervision is essential.

Can genetic testing predict exactly how well semaglutide will work for me?

No. The Precision Peptide Genetic Test reveals predispositions in appetite and metabolic pathways, not exact medication response. Genetics is one factor; clinical biomarkers, BMI, and health history matter equally. Always consult your provider.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves